Consenso peruano para el uso de la resonancia magnética en el diagnóstico y seguimiento de pacientes con esclerosis múltiple

Autores/as

  • César Caparó-Zamalloa Centro Básico de Investigación en Demencia y Enfermedades Desmielinizantes del Sistema Nervioso, Instituto Nacional de Ciencias Neurológicas. Lima, Perú. Clínica Delgado. Lima, Perú.
  • José A. Cabrejo-Bravo Hospital Nacional Almanzor Aguinaga Asenjo, EsSalud. Chiclayo, Lambayeque, Perú.
  • Carlos Castañeda-Barba Clínica “EL Golf”. Lima, Perú. Hospital Nacional Cayetano Heredia. Lima, Perú.
  • Jaqueline Cortez- Escalante Centro Básico de Investigación en Demencia y Enfermedades Desmielinizantes del Sistema Nervioso, Instituto Nacional de Ciencias Neurológicas. Lima, Perú.
  • Ana Cruz-Cruz Hospital Nacional Alberto Sabogal Sologuren, EsSalud. Callao, Perú.
  • Iván Dueñas-Pacheco Clínica Anglo Americana. Lima, Perú. Hospital María Auxiliadora. Lima, Perú.
  • Diego Escalante-Narrea Resocentro. Lima, Perú.
  • Ronald Escalante-Rojas Hospital Central de la Policía Nacional del Perú. Lima, Perú.
  • Jessica Gonzalez-Mujica Hospital Central FAP. Lima, Perú. Clínica Internacional. Lima, Perú.
  • Alembert Guevara-Vidal UNILABS-CIMEDIC. Lima, Perú.
  • Charles Huamani Hospital Nacional Adolfo Guevara Velasco. Cusco, Perú.
  • Julio C. Nisiama-Vera Hospital Nacional Carlos Alberto Seguín Escobedo, EsSalud. Arequipa, Perú. Clínica San Juan de Dios. Arequipa, Perú.
  • Carlos A. Pérez-Alviz Hospital Nacional Adolfo Guevara Velasco, EsSalud. Cusco, Perú.
  • Liliana E. Rodríguez-Kadota Clínica Delgado. Lima, Perú. Hospital Nacional Edgardo Rebagliati Martins, Lima, Perú.
  • Pamela A. Vega-Wong Clínica Internacional. Lima, Perú.

DOI:

https://doi.org/10.20453/rnp.v85i2.4227

Palabras clave:

Esclerosis múltiple, resonancia magnética, consenso, Perú

Resumen

El uso de la resonancia magnética (RM) en el diagnóstico y seguimiento de pacientes con esclerosis múltiple (EM) ha optimizado el cuidado de los pacientes afectados. Diversos grupos internacionales de trabajo han intentado clarificar y normatizar el uso global de la RM pero, en muchas ocasiones, se extrapolan datos de otras regiones que no contemplan la realidad de cada lugar o son difíciles de implementar. Objetivo: Consensuar aspectos relacionados con el uso de RM en el diagnóstico y seguimiento de pacientes con EM en el Perú. Material y Métodos: Un grupo de expertos peruanos, conformado por neurólogos y radiólogos, condujo la elaboración del consenso mediante metodología de ronda de encuestas a la distancia. Resultados: Las recomendaciones, basadas en la evidencia publicada y en el criterio de los expertos, enfocaron tanto el rol de las técnicas convencionales de RM como el de la medición de la atrofia cerebral en pacientes con EM al momento del diagnóstico y durante el periodo de seguimiento. Conclusiones: Las recomendaciones del consenso podrán potencialmente homogenizar y optimizar el cuidado y seguimiento de pacientes con EM en nuestro país.

Citas

Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7:268-77.

Montalban X, Tintore M. Multiple sclerosis in 2013: novel triggers, treatment targets and brain atrophy measures. Nat Rev Neurol. 2014;10:72-3.

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938-52.

Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018; 378:169-80.

Miller DH, Filippi M, Fazekas F, et al. Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol 2004;56:273-8.

Fazekas F, Barkhof F, Filippi M, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology. 1999;53:448-56.

Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol. 2006;5:841-52.

McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-7.

Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58:840-6.

Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.

Rovira A, Wattjes MP, Tintore M, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015;11:471-82.

Arnold DA, Li D, Hohol M, et al. Evolving role of MRI in optimizing the treatment

of multiple sclerosis: Canadian Consensus recommendations. Multiple sclerosis experimental translational clinical. 2015;1:1-9.

Wattjes MP, Rovira A, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11:597-606.

Filippi M, Absinta M, Rocca MA. Future MRI tools in multiple sclerosis. J Neurol Sci. 2013;331:14-8.

Rivera VM, Macias MA. Access and barriers to MS care in Latin America. Mult Scler J Exp Transl Clin. 2017;3:2055217317700668.

Rojas JI, Carnero E, Abad P, et al. Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM. Mult Scler Relat Disord. 2021;53:103038.

Bell BG, Spencer R, Avery AJ, Campbell SM. Tools for measuring patient safety in primary care settings using the RAND/UCLA appropriateness method. BMC Fam Pract 2014;15:110.

Santori G, Fontana I, Valente R, Ghirelli R, Valente U. Application of the RAND/UCLA Appropriateness Method to evaluate an information system for kidney/pancreas transplantation in adult recipients. Transplant Proc. 2008;40:2021-3.

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162-73.

Filippi M, Rocca MA, Bastianello S, et al. Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurological sciences.2013;34:2085-93.

Wattjes MP, Barkhof F. High field MRI in the diagnosis of multiple sclerosis: high field-high yield? Neuroradiology. 2009;51:279-92.

Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):653-670. doi: 10.1016/S1474-4422(21)00095-8

Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006;27:455-61.

Vrenken H, Jenkinson M, Horsfield MA, et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol. 2013;260:2458-71.

Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653-70.

European Medicines Agency. Gadolinium-containing contrast agents. Amsterdam: European Medicines Agency; 2017. (Citado el 15 de diciembre del 2021) Disponible en: https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents

Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB, International Society for Magnetic Resonance in M. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16:564-70.

van Waesberghe JH, Castelijns JA, Roser W, et al. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. AJNR Am J Neuroradiol. 1997;18:1279-85.

Rovira A, Auger C, Huerga E, et al. Cumulative dose of macrocyclic gadolinium-based contrast agent improves detection of enhancing lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol. 2017;38:1486-93.

Pestalozza IF, Pozzilli C, Di Legge S, et al. Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. Mult Scler. 2005;11:390-4.

Lebrun C, Bensa C, Debouverie M, et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol. 2009;66:841-6.

Jacobi C, Hahnel S, Martinez-Torres F, et al. Prospective combined brain and spinal cord MRI in clinically isolated syndromes and possible early multiple sclerosis: impact on dissemination in space and time. Eur J Neurol. 2008;15:1359-64.

Lebrun-Frenay C, Kantarci O, Siva A, et al. Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. Ann Neurol. 2020;88:407-17.

Okuda DT, Siva A, Kantarci O, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One. 2014;9:e90509.

Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013; 40:307-23.

Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA neurology. 2015;72:152-8.

Ortiz P, Bareno J, Cabrera L, Rueda K, Rovira A. Magnetic resonance imaging with gadolinium in the acute phase of relapses in multiple sclerosis. Rev Neurol. 2017; 64: 241-6.

Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009;5:553-60.

Rio J, Ruiz-Pena JL. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2016;361:158-67.

Rio J, Tintore M, Sastre-Garriga J, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol. 2012;19:899-904.

Sormani MP, De Stefano N. Defining and scoring response to IFN-beta in multiple sclerosis. Nat Rev Neurol. 2013;9:504-12.

Brisset JC, Kremer S, Hannoun S, et al. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. J Neuroradiol. 2020;47:250-8.

Freedman MS, Devonshire V, Duquette P, et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci. 2020; 47:437-55.

Lycklama G, Thompson A, Filippi M, et al. Spinal-cord MRI in multiple sclerosis. Lancet Neurol. 2003;2: 555-62.

Eden D, Gros C, Badji A, et al. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. Brain. 2019;142:633-46.

Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4:329-33.

Battaglini M, Gentile G, Luchetti L, et al. Lifespan normative data on rates of brain volume changes. Neurobiol Aging. 2019;81:30-7.

De Stefano N, Stromillo ML, Giorgio A, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:93-9.

Di Filippo M, Anderson VM, Altmann DR, et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2010;81:204-8.

Minneboo A, Jasperse B, Barkhof F, et al. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. J Neurol Neurosurg Psychiatry. 2008;79:917-23.

Khaleeli Z, Ciccarelli O, Manfredonia F, et al. Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Ann Neurol. 2008;63:790-3.

Sormani MP, Kappos L, Radue EW, et al. Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Mult Scler. 2017;23:656-64.

Zivadinov R, Jakimovski D, Gandhi S, et al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother. 2016;16:777-93.

Reuter M, Tisdall MD, Qureshi A, Buckner RL, van der Kouwe AJW, Fischl B. Head motion during MRI acquisition reduces gray matter volume and thickness estimates. Neuroimage. 2015;107:107-15.

Biberacher V, Schmidt P, Keshavan A, et al. Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. Neuroimage. 2016; 142:188-97.

Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D. Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol. 2012;69:82-8.

Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008; 71:136-44.

Duning T, Kloska S, Steinstrater O, Kugel H, Heindel W, Knecht S. Dehydration confounds the assessment of brain atrophy. Neurology. 2005;64:548-50.

Vrenken H, Jenkinson M, Horsfield MA, et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol. 2013;260:2458-71.

Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001;25:466-75.

Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016;22:1297-305.

European Society of R. Good practice for radiological reporting: Guidelines from the European Society of Radiology (ESR). Insights Imaging. 2011;2:93-6.

Soelberg P, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G. The Multiple Sclerosis Care Unit. Mult Scler. 2019;25:627-36.

Imitola J, Racke MK. Is no evidence of disease activity a realistic goal for patients with multiple sclerosis? JAMA Neurology. 2015;72:145-7.

Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263:1053-65.

Fernandez O, Rodriguez-Antiguedad A, Olascoaga J, et al. Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. Rev Neurol. 2016;62:559-69.

Rojas JI, Carnero Contentti E, Abad P, et al. Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM. Mult Scler Relat Disord. 2021;53:103038.

Descargas

Publicado

2022-06-21

Cómo citar

1.
Caparó-Zamalloa C, Cabrejo-Bravo JA, Castañeda-Barba C, Cortez- Escalante J, Cruz-Cruz A, Dueñas-Pacheco I, et al. Consenso peruano para el uso de la resonancia magnética en el diagnóstico y seguimiento de pacientes con esclerosis múltiple. Rev Neuropsiquiatr [Internet]. 21 de junio de 2022 [citado 28 de marzo de 2024];85(2):95-106. Disponible en: https://revistas.upch.edu.pe/index.php/RNP/article/view/4227

Número

Sección

ARTICULO ORIGINAL

Artículos más leídos del mismo autor/a